Shanxi C&Y Pharmaceutical Group Co Ltd Strategic Asset Allocation Index
Shanxi C&Y Pharmaceutical Group Co Ltd strategic asset allocation index. Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Strategic Asset Allocation Index of 47.8% as of June 2023. Strategic assets (PP&E of CN¥340.26 Million plus long-term investments of CN¥-) total CN¥340.26 Million, measured against net assets of CN¥711.91 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Shanxi C&Y Pharmaceutical Group Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2021)
Strategic asset allocation index of Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2021. This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Strategic Asset Allocation Index has evolved across 14 annual periods from 2008 to 2021. As of June 2023, the index stands at 47.8%, representing strategic assets of CN¥340.26 Million against net assets of CN¥711.91 Million CNY. Check Shanxi C&Y Pharmaceutical Group Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Shanxi C&Y Pharmaceutical Group Co Ltd Strategic Asset Allocation Index by Year (2008–2021)
Shanxi C&Y Pharmaceutical Group Co Ltd strategic asset allocation index by year from 2008 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2021, covering 14 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300254 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 51.9% | CN¥386.14 Million | CN¥386.14 Million | CN¥- | CN¥744.58 Million | ▲ +6.2 pp |
| 2020 | 45.7% | CN¥398.68 Million | CN¥398.68 Million | CN¥- | CN¥872.61 Million | ▲ +6.7 pp |
| 2019 | 39.0% | CN¥363.83 Million | CN¥363.83 Million | CN¥- | CN¥932.60 Million | ▼ -11.4 pp |
| 2018 | 50.4% | CN¥469.47 Million | CN¥389.69 Million | CN¥79.78 Million | CN¥931.24 Million | ▲ +1.0 pp |
| 2017 | 49.4% | CN¥480.04 Million | CN¥397.40 Million | CN¥82.65 Million | CN¥971.17 Million | ▲ +2.6 pp |
| 2016 | 46.8% | CN¥447.21 Million | CN¥353.84 Million | CN¥93.38 Million | CN¥954.85 Million | ▲ +0.3 pp |
| 2015 | 46.5% | CN¥406.12 Million | CN¥347.79 Million | CN¥58.33 Million | CN¥872.50 Million | ▲ +2.3 pp |
| 2014 | 44.2% | CN¥364.04 Million | CN¥364.04 Million | CN¥- | CN¥823.16 Million | ▼ -20.6 pp |
| 2013 | 64.8% | CN¥497.33 Million | CN¥497.33 Million | CN¥- | CN¥767.16 Million | ▲ +38.5 pp |
| 2012 | 26.4% | CN¥171.66 Million | CN¥171.66 Million | CN¥- | CN¥651.17 Million | ▲ +2.7 pp |
| 2011 | 23.6% | CN¥137.41 Million | CN¥137.41 Million | CN¥- | CN¥581.17 Million | ▼ -48.7 pp |
| 2010 | 72.3% | CN¥108.18 Million | CN¥108.18 Million | CN¥- | CN¥149.59 Million | ▲ +13.7 pp |
| 2009 | 58.6% | CN¥68.95 Million | CN¥68.95 Million | CN¥- | CN¥117.60 Million | ▼ -10.3 pp |
| 2008 | 68.9% | CN¥73.51 Million | CN¥73.51 Million | CN¥- | CN¥106.70 Million | — |